Oral fluoropyrimidine treatment of colorectal cancer

Clin Colorectal Cancer. 2001 Aug;1(2):95-103. doi: 10.3816/CCC.2001.n.009.

Abstract

5-Fluorouracil (5-FU) has been utilized as part of standard chemotherapy for treatment of early-stage and metastatic colorectal cancer for more than 4 decades. The oral fluoropyrimidines have been studied extensively as an alternative to intravenous 5-FU. The goal of such an approach is to simplify drug administration and to improve the toxicity profile while maintaining efficacy that is at least equivalent to intravenous therapy. The goal of this article is to review the features of the main oral 5-FU prodrugs, which include capecitabine, uracil and tegafur (UFT)/leucovorin, S-1, and BOF-A2 and to describe their potential efficacy in treating colorectal cancer.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Antineoplastic Combined Chemotherapy Protocols / economics
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Capecitabine
  • Clinical Trials as Topic
  • Colorectal Neoplasms / drug therapy*
  • Cost-Benefit Analysis
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology
  • Drug Combinations
  • Fluorouracil / administration & dosage*
  • Fluorouracil / adverse effects
  • Fluorouracil / analogs & derivatives*
  • Fluorouracil / metabolism
  • Fluorouracil / pharmacology
  • Humans
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin
  • Oxonic Acid / administration & dosage
  • Patient Compliance
  • Prodrugs / administration & dosage*
  • Pyridines / administration & dosage
  • Tegafur / administration & dosage
  • Treatment Outcome

Substances

  • Drug Combinations
  • Organoplatinum Compounds
  • Prodrugs
  • Pyridines
  • Oxaliplatin
  • Deoxycytidine
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Capecitabine
  • Emitefur
  • Fluorouracil